Praxis Precision Medicine...

36.20
0.33 (0.92%)
At close: Apr 02, 2025, 10:55 AM
0.92%
Bid 36.11
Market Cap 729.91M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -10.21
PE Ratio (ttm) -3.55
Forward PE -6.39
Analyst Buy
Ask 36.28
Volume 67,132
Avg. Volume (20D) 506,591.2
Open 35.14
Previous Close 35.87
Day's Range 35.00 - 36.41
52-Week Range 30.01 - 91.83
Beta 2.77

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhib...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol PRAX
Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is $105, which is an increase of 190.06% from the latest price.

Stock Forecasts

Next Earnings Release

Praxis Precision Medicines Inc. is scheduled to release its earnings on May 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
-13.08%
Praxis Precision Mediciines shares are trading low... Unlock content with Pro Subscription
1 month ago
-40.64%
Praxis Precision Medicines shares are trading lower after the company reported a Q4 EPS miss.